Skip to main content
Erschienen in: Virchows Archiv 4/2013

01.10.2013 | Original Article

Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma

verfasst von: Fumiyoshi Fushimi, Kenichi Taguchi, Hiroto Izumi, Kimitoshi Kohno, Michihiko Kuwano, Mayumi Ono, Yutaka Nakashima, Tetsuro Takesue, Seiji Naito, Yoshinao Oda

Erschienen in: Virchows Archiv | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Patients with end-stage renal disease are exposed to increased oxidative stress and impairment of antioxidant mechanisms. We focused on dialysis renal cell carcinoma (RCC), including epithelial hyperplasia in acquired cystic disease of the kidney (ACDK). We attempted to obtain insight into the carcinogenesis and tumor progression in terms of cellular defense mechanisms associated with oxidative stress by investigating the expression of antioxidant proteins by immunohistochemistry. We evaluated retrospectively 43 cases of dialysis RCC and, as a control group, 49 cases of sporadic RCC. Peroxiredoxin (Prx) 1, 3, 4, 5, and 6 expression in dialysis RCC was positively correlated with the duration of dialysis. In epithelial hyperplasia, in 17 cases of acquired cystic disease of the kidney, Prxs and thioredoxin were highly expressed. Moreover, in dialysis RCC, Prx 3, 4, and 5 immunoreactivity and nuclear expression of Y-box-binding protein-1 were higher than in sporadic RCC. In dialysis RCC, Prx 3, 4, and 5 immunoreactivity positively correlated with the Fuhrman nuclear grade. These data suggest that oxidative stress during dialysis enhances antioxidant activity, with an inhibiting effect on carcinogenesis. Once cancer has developed, antioxidant activity might have a stimulating effect on the progression of dialysis RCC.
Literatur
1.
Zurück zum Zitat Del Vecchio L, Locatelli F, Carini M (2011) What we know about oxidative stress in patients with chronic kidney disease on dialysis—clinical effects, potential treatment, and prevention. Semin Dial 24:56–64PubMedCrossRef Del Vecchio L, Locatelli F, Carini M (2011) What we know about oxidative stress in patients with chronic kidney disease on dialysis—clinical effects, potential treatment, and prevention. Semin Dial 24:56–64PubMedCrossRef
2.
Zurück zum Zitat Kuntz E, Yusenko MV, Nagy A, Kovacs G (2010) Oligoarray comparative genomic hybridization of renal cell tumors that developed in patients with acquired cystic renal disease. Hum Pathol 41:1345–1349PubMedCrossRef Kuntz E, Yusenko MV, Nagy A, Kovacs G (2010) Oligoarray comparative genomic hybridization of renal cell tumors that developed in patients with acquired cystic renal disease. Hum Pathol 41:1345–1349PubMedCrossRef
3.
Zurück zum Zitat Hori Y, Oda Y, Kiyoshima K et al (2007) Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis. J Pathol 212:218–26PubMedCrossRef Hori Y, Oda Y, Kiyoshima K et al (2007) Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis. J Pathol 212:218–26PubMedCrossRef
4.
Zurück zum Zitat Morgan MJ, Liu ZG (2011) Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res 21:103–15PubMedCrossRef Morgan MJ, Liu ZG (2011) Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res 21:103–15PubMedCrossRef
5.
Zurück zum Zitat Cossu-Rocca P, Eble JN, Zhang S, Martignoni G, Brunelli M, Cheng L (2006) Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 19:780–7PubMed Cossu-Rocca P, Eble JN, Zhang S, Martignoni G, Brunelli M, Cheng L (2006) Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 19:780–7PubMed
6.
Zurück zum Zitat Cheuk W, Lo ES, Chan AK, Chan JK (2002) Atypical epithelial proliferations in acquired renal cystic disease harbor cytogenetic aberrations. Hum Pathol 33:761–5PubMedCrossRef Cheuk W, Lo ES, Chan AK, Chan JK (2002) Atypical epithelial proliferations in acquired renal cystic disease harbor cytogenetic aberrations. Hum Pathol 33:761–5PubMedCrossRef
7.
Zurück zum Zitat Hofmann B, Hecht HJ, Flohe L (2002) Peroxiredoxins. Biol Chem 383:347–64PubMed Hofmann B, Hecht HJ, Flohe L (2002) Peroxiredoxins. Biol Chem 383:347–64PubMed
8.
Zurück zum Zitat Arnér ES, Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267:6102–9PubMedCrossRef Arnér ES, Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267:6102–9PubMedCrossRef
9.
Zurück zum Zitat Avila PC, Kropotov AV, Krutilina R, Krasnodembskay A, Tomilin NV, Serikov VB (2008) Peroxiredoxin V contributes to antioxidant defense of lung epithelial cells. Lung 186:103–114PubMedCrossRef Avila PC, Kropotov AV, Krutilina R, Krasnodembskay A, Tomilin NV, Serikov VB (2008) Peroxiredoxin V contributes to antioxidant defense of lung epithelial cells. Lung 186:103–114PubMedCrossRef
10.
Zurück zum Zitat Cha MK, Suh KH, Kim IH (2009) Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res 28:93–104PubMedCrossRef Cha MK, Suh KH, Kim IH (2009) Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res 28:93–104PubMedCrossRef
11.
Zurück zum Zitat Burke-Gaffney A, Callister ME, Nakamura H (2005) Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 26:398–404PubMedCrossRef Burke-Gaffney A, Callister ME, Nakamura H (2005) Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 26:398–404PubMedCrossRef
12.
Zurück zum Zitat Chen MF, Lee KD, Yeh CH et al (2010) Role of peroxiredoxin I in rectal cancer and related to p53 status. Int J Radiat Oncol Biol Phys 78:868–878PubMedCrossRef Chen MF, Lee KD, Yeh CH et al (2010) Role of peroxiredoxin I in rectal cancer and related to p53 status. Int J Radiat Oncol Biol Phys 78:868–878PubMedCrossRef
13.
Zurück zum Zitat Wei Q, Jiang H, Xiao Z et al (2011) Sulfiredoxin–peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. Proc Natl Acad Sci U S A 108:7004–9PubMedCrossRef Wei Q, Jiang H, Xiao Z et al (2011) Sulfiredoxin–peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. Proc Natl Acad Sci U S A 108:7004–9PubMedCrossRef
14.
Zurück zum Zitat Cohen SB, Ma W, Valova VA et al (2010) Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. Oncogene 29:403–10PubMedCrossRef Cohen SB, Ma W, Valova VA et al (2010) Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. Oncogene 29:403–10PubMedCrossRef
15.
Zurück zum Zitat Hayakawa H, Uchiumi T, Fukuda T et al (2002) Binding capacity of human YB-1 protein for RNA containing 8-oxoguanine. Biochemistry 41:12739–44PubMedCrossRef Hayakawa H, Uchiumi T, Fukuda T et al (2002) Binding capacity of human YB-1 protein for RNA containing 8-oxoguanine. Biochemistry 41:12739–44PubMedCrossRef
16.
Zurück zum Zitat Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon, IARC Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon, IARC
17.
Zurück zum Zitat Shiota M, Izumi H, Miyamoto N et al (2008) Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high-mobility group protein B1. Cancer Sci 99:1950–9PubMed Shiota M, Izumi H, Miyamoto N et al (2008) Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high-mobility group protein B1. Cancer Sci 99:1950–9PubMed
18.
Zurück zum Zitat Ohga T, Koike K, Ono M et al (1996) Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56:4224–8PubMed Ohga T, Koike K, Ono M et al (1996) Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56:4224–8PubMed
19.
Zurück zum Zitat Yasunaga M, Ohishi Y, Oda Y et al (2009) Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. Hum Pathol 40:965–74PubMedCrossRef Yasunaga M, Ohishi Y, Oda Y et al (2009) Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. Hum Pathol 40:965–74PubMedCrossRef
20.
Zurück zum Zitat Basaki Y, Hosoi F, Oda Y et al (2007) Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 26:2736–46PubMedCrossRef Basaki Y, Hosoi F, Oda Y et al (2007) Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 26:2736–46PubMedCrossRef
21.
Zurück zum Zitat Yang XJ, Tan MH, Kim HL et al (2005) A molecular classification of papillary renal cell carcinoma. Cancer Res 65:5628–37 Yang XJ, Tan MH, Kim HL et al (2005) A molecular classification of papillary renal cell carcinoma. Cancer Res 65:5628–37
22.
Zurück zum Zitat Yoshida M, Yao M, Ishikawa I et al (2002) Somatic von Hippel–Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney. Genes Chromosomes Cancer 35:359–364PubMedCrossRef Yoshida M, Yao M, Ishikawa I et al (2002) Somatic von Hippel–Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney. Genes Chromosomes Cancer 35:359–364PubMedCrossRef
23.
Zurück zum Zitat Nouh MA, Kuroda N, Yamashita M et al (2010) Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis. BJU Int 105:620–7PubMedCrossRef Nouh MA, Kuroda N, Yamashita M et al (2010) Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis. BJU Int 105:620–7PubMedCrossRef
24.
Zurück zum Zitat Oda Y, Kohashi K, Yamamoto H et al (2008) Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma. Cancer Sci 99:726–32PubMedCrossRef Oda Y, Kohashi K, Yamamoto H et al (2008) Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma. Cancer Sci 99:726–32PubMedCrossRef
26.
Zurück zum Zitat Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–63PubMedCrossRef Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–63PubMedCrossRef
27.
Zurück zum Zitat Carducci MA, Piantadosi S, Pound CR et al (1999) Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. Urology 53:44–9PubMedCrossRef Carducci MA, Piantadosi S, Pound CR et al (1999) Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. Urology 53:44–9PubMedCrossRef
28.
Zurück zum Zitat Kropotov A, Gogvadze V, Shupliakov O et al (2006) Peroxiredoxin V is essential for protection against apoptosis in human lung carcinoma cells. Exp Cell Res 312:2806–2815PubMedCrossRef Kropotov A, Gogvadze V, Shupliakov O et al (2006) Peroxiredoxin V is essential for protection against apoptosis in human lung carcinoma cells. Exp Cell Res 312:2806–2815PubMedCrossRef
29.
Zurück zum Zitat Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y (2003) Peroxiredoxins in breast carcinoma. Clin Cancer Res 9:3418–24PubMed Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y (2003) Peroxiredoxins in breast carcinoma. Clin Cancer Res 9:3418–24PubMed
30.
Zurück zum Zitat Zhang B, Wang Y, Su Y (2009) Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 286:154–60PubMedCrossRef Zhang B, Wang Y, Su Y (2009) Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 286:154–60PubMedCrossRef
31.
Zurück zum Zitat Tickoo SK, dePeralta-Venturina MN, Harik LR et al (2006) Spectrum of epithelial neoplasm in end stage renal disease: an experience from 66 tumor bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 30:141–153PubMedCrossRef Tickoo SK, dePeralta-Venturina MN, Harik LR et al (2006) Spectrum of epithelial neoplasm in end stage renal disease: an experience from 66 tumor bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 30:141–153PubMedCrossRef
Metadaten
Titel
Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma
verfasst von
Fumiyoshi Fushimi
Kenichi Taguchi
Hiroto Izumi
Kimitoshi Kohno
Michihiko Kuwano
Mayumi Ono
Yutaka Nakashima
Tetsuro Takesue
Seiji Naito
Yoshinao Oda
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 4/2013
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-013-1460-y

Weitere Artikel der Ausgabe 4/2013

Virchows Archiv 4/2013 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …